Morgan Stanley Maintains Underweight on CRISPR Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Underweight rating on CRISPR Therapeutics (CRSP) but raised the price target from $46 to $48.

February 26, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained its Underweight rating on CRISPR Therapeutics but increased the price target from $46 to $48.
The adjustment in price target by a major analyst like Morgan Stanley can influence investor sentiment. However, the maintenance of an Underweight rating suggests continued skepticism about the company's near-term prospects. This mixed signal could lead to neutral short-term price movement as the market digests both the positive adjustment in target price and the ongoing cautious stance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90